Reduced levels of CDX2 staining which is correlated with MSI, BRAF mutation, and CIMP [84, 85] were also found in the BRAF mutant/MSS cancers, which suggests that epigenetic silencing associated with CIMP and the BRAF mutation may be contributing to downregulation of CDX2 [86]. This evidence concerns the gene BRAF and cancer.